Work

Abstract CT257: SMART 2.0 Interval breast cancer reduction study: A phase 3 randomized, double-blind, placebo-controlled trial of oral Z-endoxifen in women at high risk for breast cancer

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct257

Authors: Steven C. Quay, H. Lawrence Remmel, Sandra S. Hammer, Lonnissa Nguyen, Magnus Bäcklund, Mattias Hammarström, Per Hall

Institutions: Atossa Therapeutics (United States), University Medical Center Utrecht, Karolinska Institutet

Language: English

Topic: Digital Radiography and Breast Imaging

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822050

Cites:

Cited by:

Related to: 10